Lexaria Bioscience - Lexaria Bioscience

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW
  • Home
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Board Committees

Lexaria Bioscience   →  Investor Relations   →  Board Committees
☰
  • Overview
  • Press Releases
  • Events & Presentations
  • Company Info
    • Overview
    • Management Team
    • Annual Meeting / Special Meeting
  • Analyst Coverage
  • Stock Data
  • Financial Info
    • SEC Filings
    • Quarterly Reports
    • SEDAR+
  • Legend Removal
  • Governance
    • Board of Directors
    • Governance Documents
    • Board Committees
  • Resources
    • Email Alerts
    • Investor FAQ
    • IR Contact

Board Committees

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
[email protected]

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
210 Shamrock Industrial Blvd., Suite C
Tyrone, GA 30290

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2024 Lexaria Bioscience. All rights reserved.